Cullinan Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About CGEM
All events for CGEM
All deals for CGEM
Financial Ratios
Financial Statements
CGEM vs Sector & Peers
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts. Website cullinantherapeutics.com
Headquarters Cambridge, MA, US